From Bench to Business
Lab to Launch covers lab-to-market, startup commercialization, scrappy deep tech. We publish original analysis, frameworks, and commentary for practitioners and decision-makers.
Most deep tech startups implement QMS requirements from their contract manufacturer without realizing the system is designed for their vendor's audits, not your product quality.
W. OseiSkipping an FDA pre-submission meeting feels like saving time. It usually costs 18+ months. Here's what founders get wrong and how to fix it.
W. OseiMost deep tech founders sign CRO contracts without reading the IP and data ownership clauses. Here's what you're actually giving away.
W. OseiChoosing a clinical trial site because you know the PI is one of the most common and expensive mistakes early-stage medtech and biotech founders make.
W. OseiMost medtech founders assume a CPT or ICD code will be waiting when they're ready to sell. Here's why that assumption will wreck your commercial timeline.
W. OseiThat informal equity split you shook hands on feels fine now. Here's exactly why it becomes a catastrophic problem the moment real money shows up.
W. Osei